Showing results (1-10 of 81) with videos related to

Sort By:
Pageof 9
Current Oncology Reports|March 29, 2022
Anti-PD-1: When to Stop TreatmentY Jansen, A A M van der Veldt, G Awada, et al.
Nederlands Tijdschrift Voor Geneeskunde|June 15, 2007
[Adverse effects of the tyrosine-kinase inhibitor sunitinib, a new drug for the treatment of advanced renal-cell cancer]A A M van der Veldt, A J M van den Eertwegh, E Boven
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 21, 2019
Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot studyA Rogiers, C Leys, J De Cremer, et al.
The Netherlands Journal of Medicine|October 24, 2007
Verapamil-induced erythermalgiaP W B Nanayakkara, A A M van der Veldt, S Simsek, et al.
Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace|May 20, 2004
Intratumoral gene therapy for non-small cell lung cancer: current status and future directionsB Neyns, M Noppen
Clinical Endocrinology|September 18, 2007
Hexokinase III, cyclin A and galectin-3 are overexpressed in malignant follicular thyroid nodulesL Hooft, A A M van der Veldt, O S Hoekstra, et al.
British Journal of Cancer|February 11, 2010
Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinibA A M van der Veldt, M R Meijerink, A J M van den Eertwegh, et al.
European Journal of Radiology Open|March 28, 2024
Differentiation between normal and metastatic lymph nodes in patients with skin melanoma: Preliminary findings using a DIXON-based whole-body MRI approachC Brussaard, L Faggioni, F E Ramirez-Barbosa, et al.
Current Oncology (Toronto, Ont.)|September 5, 2008
Cetuximab treatment in a patient with metastatic colorectal cancer and psoriasisB Neyns, V Meert, F Vandenbroucke
European Journal of Cancer (Oxford, England : 1990)|December 31, 2025
4-year overall survival after the introduction of adjuvant therapy for patients with stage III melanoma: A population-based studyJ C Janssen, A W Schurink, C Verhoef, et al.
Pageof 9